loading page

Clinical characteristics and risk factors for tigecycline-induced pancreatitis in a tertiary hospital: a retrospective study
  • +4
  • Wenjuan Fan,
  • Qinghai Tan,
  • Yu Zhang,
  • Mei Liu,
  • De'an Tian,
  • Xiaohui Wu,
  • Lei Zhou
Wenjuan Fan
Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology

Corresponding Author:[email protected]

Author Profile
Qinghai Tan
Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology
Author Profile
Yu Zhang
Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology
Author Profile
Mei Liu
Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology
Author Profile
De'an Tian
Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology
Author Profile
Xiaohui Wu
Dangyang Changbanpo Hospital
Author Profile
Lei Zhou
Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology
Author Profile

Abstract

Aims: To analyze the clinical characteristics and risk factors for tigecycline-induced pancreatitis (TIP) and evaluate the safety and efficiency of tigecycline use in non-TIP. Methods: A retrospective case-control study was conducted on adult and juvenile patients administered tigecycline for >3 days. The adults were classified as TIP, non-TIP (pancreatitis with other causes), and non-pancreatitis. Univariate analyses were performed to compare TIP and non-pancreatitis, and multivariate analysis was used to identify risk factors for TIP. The clinical characteristics of TIP and the safety and efficiency of tigecycline use in non-TIP were evaluated. Results: A total of 3910 patients (3823 adults and 87 juveniles) were enrolled. The adult patients comprised 21 TIP, 82 non-TIP, and 3720 non-pancreatitis. The TIP prevalences were 0.56% in adults and 1.15% in juveniles. The mean time from tigecycline use to symptom onset was 7.2 days, and all cases were mild pancreatitis. The mean time from tigecycline withdrawal to symptom relief was 3.6 days. The multivariate analysis identified comorbid renal insufficiency as an independent risk factor for TIP (odds ratio = 3.032). Among the 82 non-TIP patients, 81.7% had severe pancreatitis and 47.6% had necrotizing pancreatitis. The modified computed tomography severity score after tigecycline use was similar to that before tigecycline use, but the pancreatic enzymes and infection indices were significantly decreased. Conclusion: The prevalence of TIP was low. Comorbid renal insufficiency was as an independent risk factor for TIP. Tigecycline is safe and efficient for treatment of pancreatitis, especially necrotizing pancreatitis, with intra-abdominal infection
10 Feb 2023Submitted to British Journal of Clinical Pharmacology
11 Feb 2023Submission Checks Completed
11 Feb 2023Assigned to Editor
11 Feb 2023Review(s) Completed, Editorial Evaluation Pending
13 Feb 2023Reviewer(s) Assigned
22 Apr 2023Editorial Decision: Revise Minor
25 Apr 20231st Revision Received
25 Apr 2023Submission Checks Completed
25 Apr 2023Assigned to Editor
25 Apr 2023Review(s) Completed, Editorial Evaluation Pending
26 Apr 2023Editorial Decision: Revise Minor